US 12,331,320 B2
Genome edited cancer cell vaccines
Kaiming Ye, Vestal, NY (US); Sha Jin, Vestal, NY (US); and Subhadra Jayaraman Rukmini, Binghamton, NY (US)
Assigned to The Research Foundation for The State University of New York, Binghamton, NY (US)
Filed by The Research Foundation for the State University of new York, Binghamton, NY (US)
Filed on Oct. 9, 2019, as Appl. No. 16/596,829.
Claims priority of provisional application 62/743,801, filed on Oct. 10, 2018.
Prior Publication US 2020/0113986 A1, Apr. 16, 2020
Int. Cl. C12N 5/09 (2010.01); A61K 40/22 (2025.01); A61K 40/35 (2025.01); A61K 40/42 (2025.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01)
CPC C12N 5/0693 (2013.01) [A61K 40/22 (2025.01); A61K 40/35 (2025.01); A61K 40/4201 (2025.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 2039/5152 (2013.01); C12N 2502/99 (2013.01)] 15 Claims
 
1. A vaccine, comprising:
a non-apoptotic senescent or mitosis-arrested irradiated cell which expresses a target antigen,
wherein the cell has been genetically edited to:
express a serpin protease inhibitor;
knockout CD47;
knockout PD-L1; and
genomically integrate a gene encoding GM-CSF.